NervGen Pharma Corp. (NGEN)

NervGen Pharma Statistics

Total Valuation

NervGen Pharma has a market cap or net worth of $307.55 million. The enterprise value is $299.24 million.

Market Cap	307.55M
Enterprise Value	299.24M

Important Dates

The next estimated earnings date is Thursday, April 2, 2026.

Earnings Date	Apr 2, 2026
Ex-Dividend Date	n/a

Share Statistics

NervGen Pharma has 78.34 million shares outstanding. The number of shares has increased by 10.41% in one year.

Current Share Class	79.65M
Shares Outstanding	78.34M
Shares Change (YoY)	+10.41%
Shares Change (QoQ)	+1.68%
Owned by Insiders (%)	2.76%
Owned by Institutions (%)	-0.06%
Float	67.45M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.79

Current Ratio	0.79
Quick Ratio	0.73
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -820.11% and return on invested capital (ROIC) is -493.00%.

Return on Equity (ROE)	-820.11%
Return on Assets (ROA)	-88.77%
Return on Invested Capital (ROIC)	-493.00%
Return on Capital Employed (ROCE)	857.89%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	n/a
Profits Per Employee	-$2.62M
Employee Count	7
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +101.56% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+101.56%
50-Day Moving Average	4.62
200-Day Moving Average	3.35
Relative Strength Index (RSI)	41.17
Average Volume (20 Days)	100,902

Short Selling Information

The latest short interest is 1.31 million, so 1.67% of the outstanding shares have been sold short.

Short Interest	1.31M
Short Previous Month	n/a
Short % of Shares Out	1.67%
Short % of Float	1.94%
Short Ratio (days to cover)	9.70

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-18.12M
Pretax Income	-18.36M
Net Income	-18.36M
EBITDA	-18.09M
EBIT	-18.12M
Earnings Per Share (EPS)	-$0.26

Balance Sheet

The company has $8.16 million in cash and $23,853 in debt, with a net cash position of $8.13 million or $0.10 per share.

Cash & Cash Equivalents	8.16M
Total Debt	23,853
Net Cash	8.13M
Net Cash Per Share	$0.10
Equity (Book Value)	-2.11M
Book Value Per Share	-0.03
Working Capital	-2.42M

Cash Flow

Operating Cash Flow	-12.03M
Capital Expenditures	n/a
Free Cash Flow	-12.29M
FCF Per Share	-$0.16

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

NervGen Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-10.41%
Shareholder Yield	-10.41%
Earnings Yield	-5.97%
FCF Yield	-4.00%

Analyst Forecast

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1